Get our latest issue now

available for iOS, Android & web

latest issue

Europe green light for Sanofi MS pill Aubagio

Daily News | September 01, 2013

Kevin Grogan

Europe green light for Sanofi MS pill Aubagio

Regulators in Europe have approved Sanofi's multiple sclerosis pill Aubagio.

The European Commission has granted marketing authorisation for Aubagio (teriflunomide) as a once-daily, oral therapy for the treatment of adults with relapsing remitting MS. The approval comes after the European Medicines Agency's Committee for Human Medicinal Products issued a positive opinion on the drug in March.

The European thumbs-up is based on two Phase III trials which showed that Aubagio significantly reduced the annualised relapse rate and the time to disability progression at two years versus placebo. David Meeker, head of Sanofi's Genzyme unit, said that “Aubagio’s efficacy, safety and convenient dosing may provide an attractive treatment option".

The drug was approved in the USA in September and is also available in Australia, Argentina, Chile and South Korea. Second-quarter sales of Aubagio, which is competing in the USA with Biogen Idec's MS pill Tecfidera (dimethyl fumarate) and Novartis' Gilenya (fingolimod), reached 33 million euros.

Click here to order a reprint of this news story.


Your Comments

Tell us what you think.

Twitter Go to @PharmaTimes

Find a job

Website Search

Search News Search Magazine

Business Insight


Competitions News


International Clinical Researcher of the Year 2016

Book your tickets today!